A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Trial sites expanded: 0 → 10 locations
  2. Start date: Sep 1, 2026 to Oct 30, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 16 entries
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Roche/Genentech
368 trials monitored
See 30 trials at risk
Breast Cancer
5,466 trials monitored
See 312 trials at risk
Diabetes
5,109 trials monitored
See 234 trials at risk
Type 2 Diabetes
2,240 trials monitored
See 113 trials at risk
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
Trial Details
NCT Number NCT07748208
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Breast Cancer, Diabetes Type II
Related terms Breast Neoplasms, Diabetes Mellitus, Type 2
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov